acquired
Stage
About
Protomer Technologies develops next-generation responsive biotherapeutics, including glucose-responsive insulin receptor agonists that automatically adjust activity based on blood sugar levels using their proprietary Molecular Evolution of Peptide Sensors (MEPS) platform.
Explore Protomer Technologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.